Ovid exec Yaron Werber crosses back to Cowen; Saqib Islam promoted to SpringWorks' first CEO slot
→ While a number of analysts have been seen migrating to the front lines of biotech, Yaron Werber is moving in the opposite direction. After rotating through a couple of roles at rare disease biotech Ovid Therapeutics — and helping put together its $75 million IPO $OVID — he’s headed back to Wall Street.
The former Citigroup analyst is landing at Cowen as a managing director and senior member of its biotech team, at a time investment banks are paying big dollars to scoop popular biotech boosters from each other.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.